絞り込み

16506

広告

Successful treatment of a patient with refractory adult Still's disease by tacrolimus.

著者 Murakami K , Fujii T , Yukawa N , Yoshifuji H , Kawabata D , Tanaka M , Usui T , Mimori T
Mod Rheumatol.2007 ; 17(2):167-70.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.

スターを付ける スターを付ける     (491view , 0users)

Full Text Sources

Miscellaneous

Adult Still's disease (ASD) is a systemic rheumatic disease characterized by high spiking fever, erythema, polyarthritis, and increased levels of C-reactive protein, ferritin, and interleukin (IL)-18. Recently, biological agents targeting proinflammatory cytokines such as tumor necrosis factor (TNF) alpha, IL-1, and IL-6 have been described as effective treatments for refractory ASD. Herein, we present a patient with ASD, who was successfully treated by tacrolimus concomitant with corticosteroid, while infliximab and etanercept were not effective. Tacrolimus may be one of the drugs for the ASD patients refractory to the conventional treatments including TNF inhibitors.
PMID: 17437176 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード